Videos
Navigating the Switch From Brand Name to Biosmilar Products With Patients
October 27th 2023Jeff Cohen, MD, and Alicyn Magruder, PharmD, BCACP, MSCS, discuss the best practices when switching to a biosimilar therapy, including patient education and when to consider an insurance appeal. [WATCH TIME: 7 minutes]
Mechanistic Potential of Pepinemab, a SEMA4D-Blocking Antibody: Terrence L. Fisher, PhD
October 26th 2023The senior vice president of clinical development at Vaccinex provided commentary on a presentation from CTAD 2023 highlighting the therapeutic potential of peptinemab, an agent that’s shown success in Huntington disease, in patients with Alzheimer disease. [WATCH TIME: 3 minutes]
Therapeutic Advantages to Using EEG to Assess Alzheimer Agents: Williem de Haan, MD, PhD
October 25th 2023The neurologist and senior research at the Amsterdam University Medical Centers’ Alzheimer Center discussed the reasons behind the use of quantitative EEG in assessing Cognition Therapeutics' Alzheimer agent CT1812. [WATCH TIME: 3 minutes]
The Pharmacist Perspective on MS Biosimilars and the Possible Monitoring Needs
October 25th 2023Alicyn Magruder, PharmD, BCACP, MSCS, offers insight into the pharmacist's role in patient education on biosimilars for MS, and the group discusses the potential need for a long-term monitoring system. [WATCH TIME: 10 minutes]
Key Clinical Red Flags for Differential Diagnosis of Multiple Sclerosis: Georgina Arrambide, MD, PhD
October 23rd 2023The clinical neurologist at the MS Center of Catalunya provided perspective on her presentation from MSMilan 2023, focusing in on key factors when diagnosing multiple sclerosis from other similarly presenting disorders. [WATCH TIME: 5 minutes]
Possibilities of Measuring Cognitive Progression Independent of Relapses in MS: Tom Fuchs, MD, PhD
October 20th 2023The research fellow at the Amsterdam University Medical Center provided thoughts on the possibilities of assessing cognitive decline in clinical settings for patients with multiple sclerosis. [WATCH TIME: 5 minutes]
Appropriate Steps Needed for Integration of Biosimilars in MS Treatment Paradigm: Barry Singer, MD
October 19th 2023The director and founder of The MS Center for Innovations in Care provided thoughts on the potential role of biosimilars in treating multiple sclerosis and the steps needed to ensure that this integration process is safe. [WATCH TIME: 4 minutes]
Unpacking the Controversy of Hormone Therapy in Multiple Sclerosis: Melinda Magyari, MD
October 19th 2023The neurologist in the Danish Multiple Sclerosis Center at Copenhagen University Hospital discussed the debate surrounding the use of hormone therapy in multiple sclerosis treatment, highlighting the need for more clinical evidence to support its use. [WATCH TIME: 5 minutes]
Guiding Medical Students Through Early Career Decisions: Craig Blackstone, MD
October 18th 2023The chief of the Movement Disorders Division at Mass General Hospital discussed the challenges medical students face in pathing their career and the importance of a strong mentor figure. [WATCH TIME: 6 minutes]
The Unresolved Bottleneck of Accessing Care for Mental Health in MS: Bernd C. Kieseier, MD
October 18th 2023The global program head of the development unit for neuroscience at Novartis talked about the evolving landscape of mental health care for multiple sclerosis including the accessibility barrier that remains for patients in many regions. [WATCH TIME: 4 minutes]
AUPN Leadership Minute Episode 38: Visa Issues for Faculty
October 17th 2023Episode 38 of the AUPN Leadership Minute features Muhammad "Mud" Alvi, MD, of West Virginia University Robert C. Byrd Health; and David B. Watson, MD, of West Virginia University Robert C. Byrd Health. [WATCH TIME: 5 minutes]
Additive Potential of BTK Inhibitors in Multiple Sclerosis Treatment Paradigm: Diana Gallagher, MD
October 17th 2023The head of Biogen’s MS and Immunology Department Unit detailed the potential of combination approaches to treat MS, including the reasons for diroximel fumarate in the newly initiated phase 2 FUSION study. [WATCH TIME: 3 minutes]
Enhancing Disability Monitoring in Multiple Sclerosis Using Digital Tools: Mikael Cohen, MD
October 16th 2023The senior neurologist at the University Hospital Center of Nice in France talked about a digital tool developed to monitor disability more accurately in patients with multiple, especially during the early stages of the disease. [WATCH TIME: 5 minutes]
The Phase 2 FUSION Trial of BTK Inhibitor BIIB091: Diana Gallagher, MD
October 13th 2023The head of Biogen’s MS and Immunology Department Unit discussed FUSION, a new phase 2, 2-part study assessing the efficacy and safety of BIIB091, an investigational Bruton’s tyrosine kinase inhibitor. [WATCH TIME: 3 minutes]
Long-Term Benefits of Inebilizumab Revealed in N-MOmentum Analysis: Bruce Cree, MD, PhD, MAS, FAAN
October 13th 2023The clinical research director of the UCSF Multiple Sclerosis Center talked about a clinical trial highlighting the therapeutic benefits of longterm treatment with inebilizumab in patients with NMOSD. [WATCH TIME: 4 minutes]
The Debate About Hormone Replacement Therapy During Menopause in MS: Rhonda R. Voskuhl, MD
October 12th 2023The director of the Multiple Sclerosis Program at UCLA discussed the need to consider HRT among women with MS going through menopause, and how HRT can improve its negative effects. [WATCH TIME: 4 minutes]
Advancing Precision Medicine for Multiple Sclerosis: Mitzi Joi Williams, MD
October 12th 2023The founder and chief executive officer of Joi Life Wellness Group Multiple Sclerosis Center provided insight on the barriers with expanding precision medicine and the need for additional biomarkers of clinical progression. [WATCH TIME: 3 minutes]
Improving Care Access and Utilization for Parkinson Disease: James Beck, PhD
October 11th 2023The senior vice president and chief scientific officer of the Parkinson’s Foundation discussed a recently published Medicare claims analysis that highlighted significant issues with access to proper care for patients with Parkinson disease. [WATCH TIME: 4 minutes]
